Wall Street Zen has upgraded Henry Schein (NASDAQ:HSIC) from a "buy" to a "strong-buy" rating. This upgrade follows Henry Schein beating quarterly expectations with an EPS of $1.34 and revenue of $3.44 billion, and setting strong FY2026 guidance. Despite the upgrade, analyst sentiment is mixed, with the company holding an average "Hold" rating from MarketBeat based on various analyst recommendations.

IDEAYA Biosciences (NASDAQ:IDYA) had its stock rating upgraded by Wall Street Zen from "sell" to "hold". This comes as the company beat its latest quarterly estimates for both EPS and revenue, with the stock trading near $33.91 and a market cap of $2.98 billion. Additionally, a director recently purchased a significant amount of shares, increasing his stake in the company.

Wall Street Zen has upgraded Motorola Solutions (NYSE:MSI) from a "hold" to a "buy" rating, aligning with a consensus "Buy" rating and an average price target of $502.50 from analysts. This upgrade follows strong Q4 earnings, where MSI exceeded expectations with $4.59 EPS and $3.38 billion in revenue, coupled with robust profitability metrics. Despite significant insider selling over the past 90 days, institutional investors are increasing their stakes in the company.

Wall Street Zen has upgraded iQIYI (NASDAQ:IQ) from a "sell" to a "hold" rating. The company now holds a consensus "Hold" rating and a target price of $2.55, following mixed analyst coverage including two Buys, one Hold, and one Sell. Institutional investors currently own about 52.7% of iQIYI shares, with notable recent purchases from firms like UBS and Marshall Wace.

Wall Street Zen has upgraded PTC (NASDAQ:PTC) from a "hold" to a "buy" rating, reflecting increased analyst confidence in the company. This upgrade follows PTC's strong earnings report, where it surpassed EPS and revenue expectations and provided positive Q2 2026 EPS guidance. Despite a consensus price target indicating significant upside, the stock currently trades well below its 52-week high, with the majority of analysts rating it as a "Buy" or "Hold".

Wall Street Zen has upgraded RTX (NYSE:RTX) from a "buy" to a "strong-buy" rating, reflecting strong Q1 earnings performance where RTX beat EPS and revenue estimates, and positive operational catalysts like the EASA certification for the GTF Advantage engine. Despite these positives, the company faces near-term risks due to a relatively high P/E ratio and challenging commercial aerospace comparisons. MarketBeat reports a consensus "Moderate Buy" rating for RTX with a $203.61 price target.

Wall Street Zen has downgraded Revvity (NYSE:RVTY) from a "Buy" to a "Hold" rating, aligning with the broader analyst consensus. The company, which recently reported stronger-than-expected earnings and set a positive FY2026 guidance, nevertheless faces a "relatively rich valuation" with a P/E of 45.19. The average analyst rating is now "Hold" with an average price target of $110.17, despite various recent adjustments from other firms.

Wall Street Zen has downgraded Imperial Petroleum (IMPP) from a "buy" to a "hold" rating, aligning with a consensus "Hold" rating and an average target price of $6.00 among analysts. This follows similar downgrades and reaffirmations from other firms. Imperial Petroleum's board recently approved a $10 million share repurchase plan, and institutional ownership remains high at 94.44%.

First Industrial Realty Trust (NYSE:FR) experienced a 19.9% increase in short interest during March, reaching 4,431,476 shares, which represents about 3.4% of its outstanding shares and a short-interest ratio of 3.9 days. Despite missing quarterly EPS estimates, the company's revenue rose by 7.3%, and it announced an increased quarterly dividend of $0.50, bringing its annualized yield to 3.1%. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $63.29, following several upgrades.

Apple has successfully defended against Masimo's attempt to block imports of its smartwatches, as a U.S. trade tribunal ruled that Apple's redesigned devices do not infringe on Masimo’s patents. The U.S. International Trade Commission (ITC) closed the case after declining to review a preliminary ruling that found Apple's updated blood-oxygen monitoring technology did not violate Masimo’s intellectual property. Despite this victory, Apple remains in ongoing legal disputes with Masimo, including a separate federal court battle over trade-secret theft where Masimo secured a $634 million trial win.